This report contains market size and forecasts of Human Granulocyte Colony-stimulating Factor in global, including the following market information:
Global Human Granulocyte Colony-stimulating Factor Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Human Granulocyte Colony-stimulating Factor Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Human Granulocyte Colony-stimulating Factor companies in 2021 (%)
The global Human Granulocyte Colony-stimulating Factor market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
300μg/Dose Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Human Granulocyte Colony-stimulating Factor include Chugai Pharmaceutical, Kyowa Hakko Kirin, Sanway, GenSci, SL PHARM, Kexing Bioproducts, Qilu Pharmaceutical, CSPC and Wuzhong Pharmaceutical, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Human Granulocyte Colony-stimulating Factor manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Human Granulocyte Colony-stimulating Factor Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Human Granulocyte Colony-stimulating Factor Market Segment Percentages, by Type, 2021 (%)
300μg/Dose
150μg/Dose
75μg/Dose
Others
Global Human Granulocyte Colony-stimulating Factor Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Human Granulocyte Colony-stimulating Factor Market Segment Percentages, by Application, 2021 (%)
Hospital
Clinic
Global Human Granulocyte Colony-stimulating Factor Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Human Granulocyte Colony-stimulating Factor Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Human Granulocyte Colony-stimulating Factor revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Human Granulocyte Colony-stimulating Factor revenues share in global market, 2021 (%)
Key companies Human Granulocyte Colony-stimulating Factor sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Human Granulocyte Colony-stimulating Factor sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Chugai Pharmaceutical
Kyowa Hakko Kirin
Sanway
GenSci
SL PHARM
Kexing Bioproducts
Qilu Pharmaceutical
CSPC
Wuzhong Pharmaceutical
Quangang Pharmaceutical
Huabei Pharmaceutical
Harbin Pharmaceutical
Amoytop Biotech
Jiuyuan Gene Engineering
Four Rings Biopharmaceutical